Antonia DePace


From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

February 11th 2022

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Improved Communication Needed for Patients With RCC Subtype

September 17th 2021

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

Improvements in Cardiovascular Risk Management Needed for MPN

June 11th 2021

Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.

Lifileucel/Pembrolizumab Elicits Encouraging ORR in ICI-Naïve Advanced Melanoma

June 4th 2021

The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.

Cirmtuzumab Plus Ibrutinib Had Overall Response Rates in MCL and CLL

June 4th 2021

Cirmtuzumab and ibrutinib led to reported high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer

June 4th 2021

Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.